← Leaderboards
Tohru Ikuta
Boston University Medical Campus
$3,804,228
Attributed
$3,804,228
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $286K · FY2005–13$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$3,804,228 · 3
By mechanism
R01$2,615,129 · 2
P20$1,189,099 · 1
Top collaborators
No co-investigators on record.
Most similar at Boston University Medical Campus
Same institution · by research overlap
- Philippe Adam Grandjean$27,466,501
- Susan P Perrine$12,101,972
- Donald M Thea$37,178,572
- Robert J Ferrante$5,291,594
- Katya Ravid$16,580,337
Others in their field
Top investigators on “Sickle Cell Anemia”
- Russell E Ware · Duke University$48,435,687
- Michael Rutledge Debaun · Vanderbilt University Medical Center$38,268,866
- Martin H. Steinberg · Boston Medical Center$25,628,557
- Michael L. Terrin · Clinical Trials And Surveys Corporation$23,855,067
- Barbara L Kroner · Research Triangle Institute$21,141,016
- Garret A Fitzgerald · University Of Pennsylvania$20,602,198
Research focus
Sickle Cell AnemiaGene ExpressionCyclic GmpLaboratory MouseCgmp Dependent Protein KinaseGene Induction /RepressionDna FootprintingClinical ResearchHuman SubjectGuanylate CyclaseHemoglobin FThalassemiaBiological Signal TransductionCombined Modality TherapyAdenylate CyclaseAfrican AmericanGenetically Modified AnimalsGrowth FactorErythroid CellsGenetic Regulatory ElementArtificial ChromosomesBaseClinical EfficacyCyclic Nucleotides
Grant awards (13)
New Hydroxyurea-Based Combination Therapy for Sickle Cell Disease$104,374
P20 · FY2013 · MD · contact PI
New Hydroxyurea-Based Combination Therapy for Sickle Cell Disease$280,350
P20 · FY2012 · MD · contact PI
New Hydroxyurea-Based Combination Therapy for Sickle Cell Disease$265,039
P20 · FY2011 · MD · contact PI
New Hydroxyurea-Based Combination Therapy for Sickle Cell Disease$265,169
P20 · FY2010 · MD · contact PI
New Hydroxyurea-Based Combination Therapy for Sickle Cell Disease$274,167
P20 · FY2009 · MD · contact PI
Intracelllar Pathways That Silence the Fetal Globin Gene$279,279
R01 · FY2006 · HL · contact PI
Intracelllar Pathways That Silence the Fetal Globin Gene$286,000
R01 · FY2005 · HL
Cyclic Nucleotides and Fetal Globin Gene Expression$321,750
R01 · FY2004 · DK
Intracelllar Pathways That Silence the Fetal Globin Gene$286,000
R01 · FY2004 · HL
Cyclic Nucleotides and Fetal Globin Gene Expression$366,750
R01 · FY2003 · DK
Intracelllar Pathways That Silence the Fetal Globin Gene$316,850
R01 · FY2003 · HL
Cyclic Nucleotides and Fetal Globin Gene Expression$366,750
R01 · FY2002 · DK
Cyclic Nucleotides and Fetal Globin Gene Expression$391,750
R01 · FY2001 · DK